peppersite
Peptidesubcutaneousoral

BPC-157

BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.

Researched for
Tissue RepairSoft Tissue RecoveryTendon/Ligament RecoveryGut HealthInjury RecoveryRecovery

At a glance

Type
Peptide
Given by
subcutaneous, oral
Evidence
Systematic reviewSystematic review, across 3 audits
Reported amount
250 mcg per Peptide Dosing Protocols. All 4 sources
Typical vial
10 mg in 2 mL

How much to draw

Full calculator →
Your draw
5units
0.05 mL on a U-100 insulin syringe
5 mg/mL40 doses per vial
Vial size:
Amount per dose

Opened on 250 mcg, the figure Peptide Dosing Protocols reports for BPC-157, and a 10 mg vial in 2 mL. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for BPC-157 or for anything else, and nothing below has been checked against the study it came from.

250-500 mcg once or twice daily
Frequency
once or twice daily4-8 weeks · 4-8 week cycles, may repeat after a break
Route
subcutaneous
Reported by
Commonly published practitioner dosing range - provider confirmation required.
Standard: 250 mcg twice daily · Low: 250 mcg once daily · High: 500 mcg twice daily
Frequency
Twice daily4-6 weeks · Standard
Route
Subcutaneous injection
Reported by
Peptide Dosing Protocols
What it saysHalf-life: under 30 minutes. The standard dosing for BPC-157 is 250 mcg twice daily.
250-500 mcg
Frequency
Twice daily (morning and evening)4-6 weeks
Route
subcutaneous or oral or topical
Reported by
Peptide Protocol Wiki
Referenced at 200-500 mcg (0.2-0.5 mg) daily overall; recovery contexts cite 200-400 mcg once or twice daily, commonly right after training. Oral form referenced as viable for gut-focused use.
Frequency
1-2x daily · Morning for systemic or gut focus; post-workout for tissue repair; before bed for overnight healingOn-cycle 4-6 weeks, off-cycle 1-2 months
Route
subcutaneous, intramuscular near injury, or oral
Reported by
Peptide Therapy Reference Text
What it saysAug 2026), secondary reference; provider confirmation required.
Reconstitution, as reported
  • Commonly supplied as 5 mg or 10 mg vials · Reconstitute lyophilized powder with bacteriostatic water; refrigerate after mixing
  • 2 mL BAC water
  • Bacteriostatic water
What our audits found

How it is thought to work

In cell and rodent studies, BPC-157 appears to support angiogenesis, the growth of new blood vessels, and to change how tendon cells behave. Researchers link this to VEGFR2 activation and eNOS/nitric oxide signaling. Direct human evidence is limited to three small pilots with roughly 30 patients in total, and no Phase 2 or Phase 3 randomized trial has been published.

In technical termsPotential effects on angiogenesis, tissue signaling, and repair pathways.

What we don't know

Whether it works in people: no randomized controlled trial of BPC-157 has been published, and no Phase 2 trial has been completed. Nearly all of the evidence comes from animals and cells, with a small amount of work on human tissue outside the body.

Safety in people: there is no established human safety record. Reviews also describe a possible effect on tumour growth as a theoretical concern that has not been resolved in humans.

Independent checks: nearly every published study reports a positive effect. Our audit says that is not evidence of a problem, but it is a reason to want independent replication before treating the findings as settled.

The pairing with TB-500: our audit could not find a published controlled study that tested the two together against either one alone.

Reported side effects

Seen in studies: a 2025 infusion pilot in two adults at 10 mg and 20 mg found no adverse effects on heart, liver, kidney, thyroid or glucose markers. A 2024 interstitial cystitis pilot and a 2021 knee-pain case series described it as well tolerated in those small samples.

Reported by users: mild redness or small bumps where it is injected.

Not ruled out: an effect on tumour growth, because the blood-vessel growth pathway that supports repair also supports tumours, and reviews call this unresolved. It also affects nitric oxide signaling, which influences blood-vessel tone and so blood pressure. Most material sold in the U.S. is grey-market, so contamination, wrong dosing and degradation are separate practical risks.

Who should avoid it

People with cancer, now or in the past: it promotes blood-vessel growth in animal models, and tumours also depend on new vessels. Reviews call this a theoretical concern that has not been resolved in humans.

People who are pregnant or breastfeeding: no published human reproductive or lactation safety data exists.

Competitive or tested athletes: it has been on the World Anti-Doping Agency Prohibited List under category S0 since 2022 and remains on the 2025 list.

People on blood-pressure medicines: it affects nitric oxide signaling in animal models, which bears on vascular tone.

People seeking a regulated medical treatment: it is not an FDA-approved drug. It was removed from FDA Category 2 as of April 22, 2026. On July 23, 2026 an FDA advisory committee voted 8 to 6, with one abstention, to recommend letting pharmacies compound it. The vote does not bind the FDA, which had made no final decision when it was reported, and it is not an approval.

What gets monitored

Blood pressure monitoring during the research cycle is suggested. (reported by Peptide Dosing Protocols)

Regulatory status

FDA approval: BPC-157 is not approved by the FDA for any use. The reviews we have read tie that to the missing human trials, including no completed Phase 2 trial.

Compounding history: the FDA earlier placed BPC-157 in Category 2, its group of compounding substances flagged for significant safety risk concerns, and pharmacies that had been making it stopped. Our audit says this was not a ban on the substance. The reference entry says BPC-157 was removed from Category 2 as of April 22, 2026.

Advisory committee vote: on July 23, 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding BPC-157 to the list of substances pharmacies may compound. The vote is advisory and does not bind the FDA. Adding a substance to the list needs formal FDA rulemaking, and news reports from July 23 and 24, 2026 said the FDA had made no final decision. FDA staff scientists had objected, citing a lack of safety and effectiveness data. None of this is FDA approval of BPC-157 as a drug.

Sport: the sources behind our own pages disagree about its current World Anti-Doping Agency status, so it is not stated here. The WADA list is reissued every year.

Checked: November 2026.

Common questions

What is BPC-157?

BPC-157 stands for Body Protection Compound 157. It is a lab-made peptide of 15 amino acids, based on a sequence first identified in human gastric juice in the 1990s.

What does BPC-157 do?

In animal studies it supports new blood-vessel growth and helps cells move into injury sites. These findings come from cultured cells and rodents. A 2025 systematic review concluded that human evidence remains insufficient to back clinical guidance.

Is BPC-157 FDA-approved?

No. BPC-157 is not an FDA-approved drug. As of April 22, 2026 it was removed from FDA Category 2. On July 23, 2026 an FDA advisory committee voted 8 to 6, with one abstention, to recommend letting pharmacies compound it. The vote does not bind the FDA, which had made no final decision when it was reported, and it is not an approval.

Why is BPC-157 banned by WADA?

The source says WADA bans substances that lack regulatory approval for human use, and BPC-157 is one of them. It has been on the Prohibited List under category S0 since 2022 and remains on the 2025 list.

How is BPC-157 commonly dosed in research planning?

Reported amounts and schedules for BPC-157 differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.

Can BPC-157 be taken orally?

Oral and capsule formats are used in research, especially in gut-focused models. One paper reported that BPC-157 stays stable in human gastric juice for more than 24 hours, which is unusual for a peptide. Direct human evidence remains limited.

How is BPC-157 reconstituted?

That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.

What are the main side effects of BPC-157?

Community reports mention mild redness or small bumps at the injection site. Reviews also flag a theoretical cancer concern, because the blood-vessel growth pathway that supports repair also supports tumour growth. The small human pilots described it as well tolerated.

Sources

  1. 01Lee et al., Alternative Therapies in Health and Medicine, 2025
  2. 02Sehgal et al., Pharmaceuticals, 2025
  3. 03He et al., Frontiers in Pharmacology, 2022
  4. 04Sikiric et al., Current Pharmaceutical Design, 2011

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.

Studied for the same things